Pfizer vaccine reduces rate of symptomatic infections by 94%, research shows
Study also shows that a week after receiving the second dose, the vaccine is 91-99% efficient in preventing the pathogen from evolving into a serious illness; results expected to become much more accurate as time passes and as more Israelis pass the-two week benchmark after second jab
Adir Yanko, Yaron Druckman |
Published: 02.14.21 , 22:10
Research conducted by the Clalit Health Fund released Sunday shows that Pfizer’s coronavirus vaccine is exceptionally effective in preventing infection and severe illness in all age groups, including those aged 70 and over.
The study includes data on some 1.2 million Israelis insured by Clalit, of whom about 600,000 have received both doses of the Pfizer’s vaccine.